Search
forLearn
5 / 801 resultslearn procapil
learn Calcipotriene
learn Ciclopirox
learn oleanolic acid
Research
5 / 1000+ results
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.
research Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy
DPCP may be safe for treating alopecia during pregnancy, but more research is needed.
research Bicalutamide
research Bioavailability File: Bicalutamide
Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
Community Join
5 / 1000+ resultscommunity Alpicort E: Diffuse thinning/MPB medication, Can't find much info on it?
A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.
community Pyrilutamide available at Actifolic now
Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community [Part 2] – Sharing data for collaborative analytics on pyrilutamide
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.